imatinib mesylate has been researched along with Cardiomegaly in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barr, LA; Berretta, RM; Force, T; Gao, H; Houser, SR; Kubo, H; Makarewich, CA; Recchia, F; Troupes, CD; Woitek, F | 1 |
| Kim, DH; Kim, JG; Lee, KB; Sohn, SK | 1 |
| Kio, EA; Lazarchick, J; Onitilo, AA; Singh, AK | 1 |
3 other study(ies) available for imatinib mesylate and Cardiomegaly
| Article | Year |
|---|---|
Imatinib activates pathological hypertrophy by altering myocyte calcium regulation.
Topics: Animals; Apoptosis; Benzamides; Calcineurin; Calcium; Calcium Signaling; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cardiomegaly; Cell Nucleus; Heart Ventricles; Imatinib Mesylate; Mice; Myocytes, Cardiac; NFATC Transcription Factors; Phosphorylation; Piperazines; Protein Transport; Pyrimidines; Rats, Sprague-Dawley | 2014 |
Cardiac morbidity in advanced chronic myelogenous leukaemia patients treated by successive allogeneic stem cell transplantation with busulphan/cyclophosphamide conditioning after imatinib mesylate administration.
Topics: Adult; Antineoplastic Agents; Benzamides; Busulfan; Cardiomegaly; Cyclophosphamide; Echocardiography, Doppler; Electrocardiography; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung; Male; Piperazines; Pyrimidines; Radiography; Reoperation; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous | 2003 |
Cytogenetic remission with imatinib therapy in hypereosinophilic syndrome with trisomy 8 and resolution of severe cardiac dysfunction.
Topics: Aortic Valve Insufficiency; Benzamides; Cardiomegaly; Chromosomes, Human, Pair 8; Cytogenetic Analysis; Heart Diseases; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Middle Aged; Mitral Valve Insufficiency; Piperazines; Pyrimidines; Remission Induction; Trisomy | 2005 |